Gasporox (GPX) Investing in Life Science 2026 summary

Technology and product innovation

• Developed laser-based, non-destructive inspection technology for pharmaceutical packaging, enabling rapid, inline testing of vials, ampules, and now tablets.

• Expanded applications from parenteral drugs to oral solids, launching a CE-marked tablet inspection product by year-end.

• Technology also serves food and beverage industries, supporting modified atmosphere packaging for extended shelf life.

• Inline sensors and lab solutions (Lab Luna) offer both feasibility studies and regulatory support for customers.

• New LineArch inline solution installed in Europe, marking a shift to turnkey provider.

Market position and growth

• Achieved around 1,000 global installations, with technology used in vaccine and drug safety assurance.

• Focused initially on pharmaceuticals, with significant expansion potential in food and beverage sectors (up to 200,000 lines combined).

• Plateaued at SEK 30 million turnover, maintaining positive EBITDA and ongoing investments for growth.

• Listed on Nasdaq First North Growth Market, supported by stable, large owners.

• Multiple growth vectors identified in pharma, food, and oral solids.

Regulatory and industry adoption

• Technology recommended in United States Pharmacopeia and EU GMP Annex 1, aligning with industry shift to deterministic testing.

• Regulatory requirements drive adoption, especially for new drugs, but legacy methods like blue dye testing still permitted for older approvals.

• Adoption in life sciences is slow due to industry conservatism and need for extensive validation.

• Company assists clients with regulatory studies, method development, and compliance training.

• Software is 21 CFR Part 11 compliant, facilitating integration into pharma quality systems.